INVO Fertility Inc (IVF) Stock Analysis
Verdict: AVOID
Severe capital depletion and consistent earnings failures outweigh niche clinical wins; the model views this as a high-risk dilution trap.
Investment score: 18/100
Analysis as of
Is INVO Fertility Inc stock worth reviewing? AI model thesis
The model recommends avoiding IVF due to extreme financial instability, a history of massive earnings misses, and a capital structure that suggests imminent further dilution.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 2/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
INVO Fertility Inc opportunities and risks
What speaks for IVF
- Proprietary INVOcell technology adoption
What speaks against IVF
- Insolvency and Liquidity Crunch
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| IVF | n/a | 0.3x | n/a | 33.3% | -70.2% | -254.0% |
| XAIR | n/a | 0.5x | n/a | 4.2% | -435.7% | -549.5% |
| GCTK | n/a | 0.0x | n/a | 0.0% | 0.0% | -621.2% |
| PFSA | n/a | 0.0x | n/a | 0.0% | 0.0% | -354.5% |
| LGMK | n/a | 0.1x | 0.5x | 64.7% | -50.8% | -473.0% |
| LLBO | n/a | 0.0x | n/a | 0.0% | 0.0% | 0.0% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -473.0% |
Frequently asked questions about INVO Fertility Inc (IVF)
Is IVF stock a good investment?
The cached TradeMates AI model rates INVO Fertility Inc as AVOID with an investment score of 18/100. The model recommends avoiding IVF due to extreme financial instability, a history of massive earnings misses, and a capital structure that suggests imminent further dilution. This is algorithmic model output, not personal investment advice.
Is IVF stock a buy?
The TradeMates model verdict for IVF is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.